Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 8933 results

  1. Leadless cardiac pacemaker implantation for bradyarrhythmias

    In development Reference number: GID-IPG10340 Expected publication date:  25 February 2026

  2. Transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitation

    In development Reference number: GID-IPG10416 Expected publication date:  25 February 2026

  3. Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]

    In development Reference number: GID-TA11385 Expected publication date:  25 February 2026

  4. Off-pump minimal access mitral valve repair by artificial chordae insertion to treat mitral regurgitation

    In development Reference number: GID-IPG10216 Expected publication date:  25 February 2026

  5. Blood transfusion - Tranexamic acid (update)

    In development Reference number: GID-NG10441 Expected publication date:  26 February 2026

  6. Rare diseases

    In development Reference number: GID-QS10197 Expected publication date:  27 February 2026

  7. Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]

    In development Reference number: GID-TA11545 Expected publication date:  11 February 2026

  8. Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer [ID6168]

    In development Reference number: GID-TA11115 Expected publication date:  02 March 2026

  9. Pegzilarginase for treating arginase-1 deficiency in people 2 years and over [ID4029]

    In development Reference number: GID-HST10054 Expected publication date:  04 March 2026

  10. Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils [ID6235]

    In development Reference number: GID-TA11246 Expected publication date:  05 March 2026

  11. Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]

    In development Reference number: GID-TA11561 Expected publication date:  11 March 2026

  12. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]

    In development Reference number: GID-TA10979 Expected publication date:  11 March 2026

  13. Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487]

    In development Reference number: GID-TA11628 Expected publication date:  11 March 2026

  14. Suspected neurological conditions: recognition and referral (NG127)

    This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

  15. Safeguarding adults in care homes (NG189)

    This guideline covers keeping adults in care homes safe from abuse and neglect. It includes potential indicators of abuse and neglect by individuals or organisations, and covers the safeguarding process from when a concern is first identified through to section 42 safeguarding enquiries. There are recommendations on policy, training, and care home culture, to improve care home staff awareness of safeguarding and ensure people can report concerns when needed.